Dr. Smitha S. Krishnamurthi, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 103
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Perelman School of Med at the University of Pennsylvania
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
OH license 35-078364
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Hillcrest Hospital Mayfield Heights, OH
- Akron General Medical Center Akron, OH
- Cleveland Clinic Avon Hospital Avon, OH
- Mercy Medical Center Canton, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 103
- Services billed
- 338
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 87 | 44 |
| Established patient office or other outpatient visit, 20-29 minutes | 65 | 37 |
| Established patient office or other outpatient visit, 40-54 minutes | 39 | 31 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Olanzapine Other prescribers in Cleveland, OH | 43 |
| Xarelto (rivaroxaban) Other prescribers in Cleveland, OH | 26 |
| Ondansetron Hcl Other prescribers in Cleveland, OH | 26 |
| Potassium Chloride Other prescribers in Cleveland, OH | 24 |
| Eliquis (apixaban) Other prescribers in Cleveland, OH | 20 |
| Dexamethasone Other prescribers in Cleveland, OH | 17 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Cleveland, OH | 14 |
| Fruzaqla (fruquintinib) | 13 |
| Furosemide Other prescribers in Cleveland, OH | 13 |
| Loperamide (loperamide hcl) Other prescribers in Cleveland, OH | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $3,600 in total to this clinician.
| Exelixis Inc. | $1,800 |
|---|---|
| AbbVie Inc. | $1,800 |
| Honoraria | $1,800 |
|---|---|
| Consulting Fee | $1,800 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jan 30, 2025 | Consulting Fee | $1,800 |
| Exelixis Inc. Dec 12, 2025 | Honoraria CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid | $1,800 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $66,301 in research payments for these studies, mostly to the institutions running them.
- A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie Inc. · Active, not recruiting · NCT06614192 - A Phase 1b,2 Open-Label, Dose Escalation of ADG106 in Combination with Pembrolizumab Anti PD-1 Antibody and Expansion of ADG106 with or without Pembrolizumab in Patients with Advanced or Metastatic Solid and,or Hemato…
Merck Sharp & Dohme LLC - An openlabel multicenter randomized phase 3 study of firstline encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety leadin of encorafenib and cetuximab plus chemotherap…
Pfizer Inc. - A phase 3, open-label, randomized study of perioperative dostarlimab m
GlaxoSmithKline, LLC. - BNT314-02
BioNTech SE
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.